Cardiff Oncology announced positive data from a Phase 1b clinical trial of onvansertib combined with paclitaxel for metastatic triple-negative breast cancer (mTNBC). The trial, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, showed a 40% objective response rate at the highest onvansertib dose, with the combination demonstrating a tolerable safety profile. The majority of patients had received multiple prior chemotherapy regimens.
This data is particularly important for mTNBC patients, who often face limited treatment options after progressing on standard therapies. The 40% response rate, even in heavily pretreated patients, some of whom had prior paclitaxel exposure, suggests this combination could offer a new line of attack against this aggressive cancer. The manageable toxicity profile further strengthens its potential as a viable treatment option, potentially improving quality of life for these patients.
The Phase 1b trial was a dose-escalation study aimed at evaluating the safety and efficacy of onvansertib plus paclitaxel. The 40% objective response rate was observed at the recommended Phase 2 dose of 18mg/m² of onvansertib. Myelosuppression was the most common adverse event, and the combination was deemed well-tolerated. The trial included patients who had received a median of three prior lines of chemotherapy, highlighting the potential of this combination in later-line treatment settings.
These positive results support further investigation of onvansertib plus paclitaxel for mTNBC. This combination could represent a significant advancement in treatment options for this challenging cancer type, potentially leading to improved outcomes and quality of life for patients. Future research will focus on confirming these findings in larger clinical trials and exploring potential applications in earlier treatment settings.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
